Medication discount card

Simply enter your information below

We will never sell your information to any third parties

You will receive your card in about one week. In the mean time you may print a card now and start using it immediately

Looking for a Livalo Coupon?

Save Up To 75% With This Livalo Discount Card!

Looking for a Livalo Coupon?

Save Up To 75% With This Livalo Discount Card!

Estimated Savings Of Over $1,003,096
PR Featured On
  • ABC
  • NBC
  • FOX
  • CBS
  • San Francisco Chronicle
  • About.com
  • CIO
  • Boston.com

Always pay a fair price for your medication!

Our FREE Livalo discount card helps you save money on the exact same Livalo prescription you're already paying for. Print the card in seconds, then take it to your pharmacy the next time you get your Livalo prescription filled. Hand it to them and save between 10% - 75% off this prescription!

Livalo, also known as pitavastatin, belongs to the "statins" group of drugs. Livalo decreases bad cholesterol levels and increases good cholesterol levels. It is used to treat high levels of cholesterol in adults. It can also help prevent heart disease, hardening of the arteries, and other conditions that can contribute to stroke, heart attack, and other forms of vascular disease. Your doctor may prescribe Livalo for other uses as well. Did you know that you might be able to save on your prescription with a Livalo coupon or a Livalo discount card?

Livalo Side Effects
Livalo works well at reducing cholesterol and lowering the risks of many life-threatening diseases. However, it does have its side effects. If you have concerns about any Livalo side effects, discuss them with your doctor. Side effects can include:
  • Nausea
  • Chills
  • Diarrhea
  • Fever
  • Generally feeling ill or uncomfortable
  • Runny nose
  • Sore throat
  • Headache
  • Cough
Price of Livalo
Many patients are concerned about affording the price of Livalo. To decrease your cost, use a Livalo discount card. The Livalo discount card has saved many patients significant amounts on their Livalo prescriptions. Contact your pharmacy today to see if they accept prescription drug discount cards. To get your own Livalo discount card, just click the "Print Card Now" button and start saving today!

Sources:
"Livalo." Information from Drugs.com. Cerner Multum, Inc., 24 July 2012. Web. 25 Sept. 2013.
"Livalo." Kowa Pharmaceuticals America, Inc., July 2013. Web. 25 Sept. 2013.
TALKED ABOUT IN
  • ABC
  • NBC
  • FOX
  • CBS
  • San Francisco Chronicle
  • About.com
  • CIO
  • Boston.com
Estimated Savings Of Over $1,003,096

Always pay a fair price for your medication!

Our FREE Livalo discount card helps you save money on the exact same Livalo prescription you're already paying for. Print the card in seconds, then take it to your pharmacy the next time you get your Livalo prescription filled. Hand it to them and save between 10% - 75% off this prescription!

Livalo, also known as pitavastatin, belongs to the "statins" group of drugs. Livalo decreases bad cholesterol levels and increases good cholesterol levels. It is used to treat high levels of cholesterol in adults. It can also help prevent heart disease, hardening of the arteries, and other conditions that can contribute to stroke, heart attack, and other forms of vascular disease. Your doctor may prescribe Livalo for other uses as well. Did you know that you might be able to save on your prescription with a Livalo coupon or a Livalo discount card?

Livalo Side Effects
Livalo works well at reducing cholesterol and lowering the risks of many life-threatening diseases. However, it does have its side effects. If you have concerns about any Livalo side effects, discuss them with your doctor. Side effects can include:
  • Nausea
  • Chills
  • Diarrhea
  • Fever
  • Generally feeling ill or uncomfortable
  • Runny nose
  • Sore throat
  • Headache
  • Cough
Price of Livalo
Many patients are concerned about affording the price of Livalo. To decrease your cost, use a Livalo discount card. The Livalo discount card has saved many patients significant amounts on their Livalo prescriptions. Contact your pharmacy today to see if they accept prescription drug discount cards. To get your own Livalo discount card, just click the "Print Card Now" button and start saving today!

Sources:
"Livalo." Information from Drugs.com. Cerner Multum, Inc., 24 July 2012. Web. 25 Sept. 2013.
"Livalo." Kowa Pharmaceuticals America, Inc., July 2013. Web. 25 Sept. 2013.
7 Great Reasons To Print Your Livalo Discount Card Today
  • 1) 100% FREE (no fees, ever)
  • 2) Print and use immediately
  • 3) Everyone qualifies
  • 4) Easy to use
  • 5) No paperwork
  • 6) Unlimited uses and no expiration date
  • 7) Accepted at over 59,000 pharmacies nationwide!
Livalo prescribing information
This information is not for clinical use. These highlights do not include all the information needed to use Livalo safely and effectively.
Before taking Livalo please consult with your doctor. See full prescribing information for Livalo.
1 INDICATIONS AND USAGE Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate. LIVALO is a HMG-CoA reductase inhibitor indicated for: Patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) (1.1) Limitations of Use (1.2): Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO. The effect of LIVALO on cardiovascular morbidity and mortality has not been determined. LIVALO has not been studied in Fredrickson Type I, III, and V dyslipidemias. 1.1 Primary Hyperlipidemia and Mixed Dyslipidemia LIVALO® is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. 1.2 Limitations of Use Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO. The effect of LIVALO on cardiovascular morbidity and mortality has not been determined. LIVALO has not been studied in Fredrickson Type I, III, and V dyslipidemias.
3 DOSAGE FORMS AND STRENGTHS 1 mg: Round white film-coated tablet. Debossed “KC” on one side and “1” on the other side of the tablet. 2 mg: Round white film-coated tablet. Debossed “KC” on one side and “2” on the other side of the tablet. 4 mg: Round white film-coated tablet. Debossed “KC” on one side and “4” on the other side of the tablet. Tablets: 1 mg, 2 mg, and 4 mg (3)
4 CONTRAINDICATIONS The use of LIVALO is contraindicated in the following conditions: Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with LIVALO [see Adverse Reactions (6.1)]. Patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels [see Warnings and Precautions (5.2), Use in Specific Populations (8.7)]. Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, LIVALO may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.2)]. Nursing mothers. Animal studies have shown that LIVALO passes into breast milk. Since HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, LIVALO, like other HMG-CoA reductase inhibitors, is contraindicated in pregnant or nursing mothers [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.2)]. Co-administration with cyclosporine [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Known hypersensitivity to product components (4) Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4) Women who are pregnant or may become pregnant (4, 8.1) Nursing mothers (4, 8.3) Co-administration with cyclosporine (4, 7.1, 12.3)
5 WARNINGS AND PRECAUTIONS Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase in a dose-dependent manner, with advanced age (≥65), renal impairment, and inadequately treated hypothyroidism. Advise patients to promptly report unexplained and/or persistent muscle pain, tenderness, or weakness, and discontinue LIVALO (5.1) Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (5.2) 5.1 Skeletal Muscle Effects Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including LIVALO. These risks can occur at any dose level, but increase in a dose-dependent manner. LIVALO should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (≥65 years), renal impairment, and inadequately treated hypothyroidism. The risk of myopathy may also be increased with concurrent administration of fibrates or lipid-modifying doses of niacin. LIVALO should be administered with caution in patients with impaired renal function, in elderly patients, or when used concomitantly with fibrates or lipid-modifying doses of niacin [see Drug Interactions (7.6), Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)]. Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine [see Drug Interactions (7.7)]. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. LIVALO therapy should be discontinued if markedly elevated creatine kinase (CK) levels occur or myopathy is diagnosed or suspected. LIVALO therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures). All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing LIVALO. 5.2 Liver Enzyme Abnormalities Increases in serum transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including LIVALO. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. In placebo-controlled Phase 2 studies, ALT >3 times the upper limit of normal was not observed in the placebo, LIVALO 1 mg, or LIVALO 2 mg groups. One out of 202 patients (0.5%) administered LIVALO 4 mg had ALT >3 times the upper limit of normal. It is recommended that liver enzyme tests be performed before the initiation of LIVALO and if signs or symptoms of liver injury occur. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pitavastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with LIVALO, promptly interrupt therapy. If an alternate etiology is not found do not restart LIVALO. As with other HMG-CoA reductase inhibitors, LIVALO should be used with caution in patients who consume substantial quantities of alcohol. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of LIVALO [see Contraindications (4)]. 5.3 Endocrine Function Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIVALO.
6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [see Warnings and Precautions (5.1)]. Liver Enzyme Abnormalities [see Warning and Precautions (5.2)]. Of 4,798 patients enrolled in 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 patients were administered pitavastatin 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years – 89 years) and the gender distribution was 48% males and 52% females. Approximately 93% of the patients were Caucasian, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other. The most frequent adverse reactions (rate ≥2.0% in at least one marketed dose) were myalgia, back pain, diarrhea, constipation and pain in extremity. (6) To report SUSPECTED ADVERSE REACTIONS, contact Kowa Pharmaceuticals America, Inc. at 1-877-334-3464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies on LIVALO are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of LIVALO cannot be directly compared with that in the clinical studies of other HMG-CoA reductase inhibitors and may not reflect the frequency of adverse reactions observed in clinical practice. Adverse reactions reported in ≥ 2% of patients in controlled clinical studies and at a rate greater than or equal to placebo are shown in Table 1. These studies had treatment duration of up to 12 weeks. Table 1. Adverse Reactions* Reported by ≥2.0% of Patients Treated with LIVALO and > Placebo in Short-Term Controlled Studies * Adverse reactions by MedDRA preferred term. Adverse Reactions* Placebo N= 208 LIVALO 1 mg N=309 LIVALO 2 mg N=951 LIVALO 4 mg N=1540 Back Pain 2.9% 3.9% 1.8% 1.4% Constipation 1.9% 3.6% 1.5% 2.2% Diarrhea 1.9% 2.6% 1.5% 1.9% Myalgia 1.4% 1.9% 2.8% 3.1% Pain in extremity 1.9% 2.3% 0.6% 0.9% Other adverse reactions reported from clinical studies were arthralgia, headache, influenza, and nasopharyngitis. The following laboratory abnormalities have also been reported: elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, and glucose. In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin-treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and myalgia (0.5% on 4 mg). Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with LIVALO. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of LIVALO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions associated with LIVALO therapy reported since market introduction, regardless of causality assessment, include the following: abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, fatigue, malaise, hepatitis, jaundice, fatal and non-fatal hepatic failure, dizziness, hypoesthesia, insomnia, depression, interstitial lung disease, erectile dysfunction and muscle spasms. There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see Warnings and Precautions (5.1)].
7 DRUG INTERACTIONS Erythromycin: Combination increases pitavastatin exposure. Limit LIVALO to 1 mg once daily (2.3, 7.2) Rifampin: Combination increases pitavastatin exposure. Limit LIVALO to 2 mg once daily (2.4, 7.3) Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with LIVALO. (5.1, 7.4, 7.5) 7.1 Cyclosporine Cyclosporine significantly increased pitavastatin exposure. Co-administration of cyclosporine with LIVALO is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3)]. 7.2 Erythromycin Erythromycin significantly increased pitavastatin exposure. In patients taking erythromycin, a dose of LIVALO 1 mg once daily should not be exceeded [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. 7.3 Rifampin Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. 7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of LIVALO with gemfibrozil should be avoided. 7.5 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIVALO should be administered with caution when used concomitantly with other fibrates [see Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)]. 7.6 Niacin The risk of skeletal muscle effects may be enhanced when LIVALO is used in combination with niacin; a reduction in LIVALO dosage should be considered in this setting [see Warnings and Precautions (5.1)]. 7.7 Colchicine Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine. 7.8 Warfarin LIVALO had no significant pharmacokinetic interaction with R- and S- warfarin. LIVALO had no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin treatment [see Clinical Pharmacology (12.3)]. However, patients receiving warfarin should have their PT and INR monitored when pitavastatin is added to their therapy.
8 USE IN SPECIFIC POPULATIONS Pediatric use: Safety and effectiveness have not been established. (8.4) Renal impairment: Limitation of a starting dose of LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily for patients with moderate and severe renal impairment as well as patients receiving hemodialysis (2.2, 8.6) 8.1 Pregnancy Teratogenic effects: Pregnancy Category X LIVALO is contraindicated in women who are or may become pregnant. Serum cholesterol and TG increase during normal pregnancy, and cholesterol products are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hyperlipidemia therapy [see Contraindications (4)]. There are no adequate and well-controlled studies of LIVALO in pregnant women, although, there have been rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors. In a review of about 100 prospectively followed pregnancies in women exposed to other HMG-CoA reductase inhibitors, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified. Reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at ≤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation. Embryo-fetal developmental studies were conducted in pregnant rats treated with 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis. No adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on AUC. Embryo-fetal developmental studies were conducted in pregnant rabbits treated with 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis. Maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on AUC). In perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning, maternal toxicity consisting of mortality at ≥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on AUC). LIVALO may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking LIVALO, the patient should be apprised of the potential risks to the fetus and the lack of known clinical benefit with continued use during pregnancy. 8.3 Nursing Mothers It is not known whether pitavastatin is excreted in human milk, however, it has been shown that a small amount of another drug in this class passes into human milk. Rat studies have shown that pitavastatin is excreted into breast milk. Because another drug in this class passes into human milk and HMG-CoA reductase inhibitors have a potential to cause serious adverse reactions in nursing infants, women who require LIVALO treatment should be advised not to nurse their infants or to discontinue LIVALO [see Contraindications (4)]. 8.4 Pediatric Use Safety and effectiveness of LIVALO in pediatric patients have not been established. 8.5 Geriatric Use Of the 2,800 patients randomized to LIVALO 1 mg to 4 mg in controlled clinical studies, 1,209 (43%) were 65 years and older. No significant differences in efficacy or safety were observed between elderly patients and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. 8.6 Renal Impairment Patients with moderate and severe renal impairment (glomerular filtration rate 30 – 59 mL/min/1.73 m2 and 15 – 29 mL/min/1.73 m2 not receiving hemodialysis, respectively) as well as end-stage renal disease receiving hemodialysis should receive a starting dose of LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. 8.7 Hepatic Impairment LIVALO is contraindicated in patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels.

Save on the cost of Livalo

With Our Livalo Discount Card

Be sure to ask your pharmacist not to substitute another card for ours as we are confident we offer the highest savings possible.

Medication Discount Card Medication Discount Card
Frequently Asked Questions

There are no catches to this. Simply print the card, take it to your pharmacy, and save. If you still have questions just read below...

How Do I Know My Pharmacy Will Accept It?
That's simple. The card is accepted at ALL CHAIN PHARMACIES such as CVS, Rite Aid, and Walgreens. If you don't know if your pharmacy accepts the card simply call them and give them the BIN and PCN numbers on the card. The card is accepted at most pharmacies. If you call a few one is sure to accept it.
Can I Use This In Conjunction With My Insurance?
No, unfortunately insurance companies don't allow "double-savings". However, if your insurance does not cover certain drugs (ex - cosmetic drugs, brand names, prenatal vitamins, etc) then this card may save you money. Also if your insurance requires you to pay a deductible on your brand name drugs before covering them, then this card may also provider greater savings!
How Much Will This Card Save Me?
You can expect to save between 10% - 75% off standard retail pricing. The discount varies depending on what type and brand of drug (generic or brand-name) you are purchasing.
This Sounds Too Good To Be True. Is This A Scam?
Absolutely not. As you can see there are no fees, ever. We will never ask for credit card information at any time. The reason this card works is simply because pharmacies are willing to provide a discount in order to earn your business.
My Pharmacy Isn't Included. Can They Participate?
Yes! There are pharmacies who accept the pharmacy savings card that are not on our list. If you find one please email us and we'll update the list. If they are not a current partner and are interested, email us and we'll contact them to try and convince them to participate. You may also choose to call around and see if someone else in your area accepts it.
Is this the same as a Livalo copay card?
No this is not a copay card, It is good for the cash paying customer and cannot be used to reduce your copay.
Savings of 70%!
I want to thank you for your prescription card. My thyroid medicine was going to cost me $118 a month. Well, naturally, I thought of your card. Your site said for my 240 tablets a month it would be about $36. A savings of $82, or roughly 70%. Thank you for the relief your card has previously given to me now and in the past. - J. Donaldson
Savings of over $200!
Thank you for putting the medication discount card on the internet. I saved over 200 dollars On my prescription. I would have never been able to afford it had it not been for this product. Again I cannot thank you enough and keep up the good work!! - M. Axler
Savings of over 50%!
I had printed out 3 different discount cards on the internet and asked the pharmacist to check prices. The lowest price was $289. I searched the internet some more, I found this site, gave the pharmacy your card and the cost was $130. What a big savings, I can't thank this site enough. - Linda S.

Accepted at over 59,000 pharmacies nationwide including

Accepted At Over 59,000 Pharmacies Nationwide!

Including...
  • Including...
  • Cub Pharmacy
  • Kmart
  • HEB
  • Target
  • Winn Dixie
  • Costco
  • Safeway
  • Kroger
  • Tom Thumb
  • CVS
  • Brookshire`s
  • Rite Aid
  • Fred`s Pharmacy
  • Walmart
  • Long Drugs
  • Walgreens
  • Giant
  • Save Mart Pharmacy
  • Fred Meyer
  • We Care Pharmacy
  • Albertsons

And thousands of independent pharmacies nationwide!

Pitavastatin (usually as a calcium salt) is a member of the medication class of statins, marketed in the United States under the trade name Livalo. Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. It has been available in Japan since 2003, and is being marketed under licence in South Korea and in India. It is likely that pitavastatin will be approved for use in hypercholesterolaemia (elevated levels of cholesterol in the blood) and for the prevention of cardiovascular disease outside South and Southeast Asia as well.

Wikipedia contributors. "Livalo" Wikipedia, The Free Encyclopedia. Wikipedia, The Free Encyclopedia, Jul 3, 2012. Web. Jul 6, 2012.

Livalo Coupon

Currently we do not have any available, however you can receive an instant discount at your pharmacy with our Livalo discount card. Create one instantly

Important Note

The information on this website is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. Consult your healthcare professional before using this drug.

This prescription discount card cannot be used in conjunction with insurance. However, some members find they save more when using the card rather than there prescription coverage.

This Livalo discount should not be confused with a Livalo coupon while they are essentially the same this discount card only needs to be handed to your pharmacist once and will provide continuous savings every time your prescription is filled. The only time you will need to use it again is if you change pharma

MedicationDiscountCard.com offers Average Savings of
60.04%
Compare us with the competition
  • Free Membership
  • No Health Restrictions
  • Use Immediately
  • Easy To Use
  • No Paperwork
  • Unlimited Use
  • Never Expires
"I went to a chain pharmacy today and wanted to fill a prescription and not run it through my insurance.They quoted me $164.00 for a 90 day generic supply, I asked them to double check and it was the best they could do. I came home, checked your online price, registered and had a card in 15 seconds. Went back, and the prescription was $16.92!"
"FYI the pharmacist asked for the website and wants it to refer customers in store directly. I don’t quite understand how it works, but honestly, I don’t care how it works, it did!!!!"
- Ivan S.
Save up to 75% on your medication
Save up to 75% on your medication